Ten years preceding a diagnosis of neurodegenerative disease in Europe and Australia: medication use, health conditions, and biomarkers associated with Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosisResearch in context
Summary: Background: Many studies have investigated early predictors for Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). However, evidence is sparse regarding specific and common predictors for these diseases. We aimed to identify medication us...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | EBioMedicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352396425000295 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832087568539189248 |
|---|---|
| author | Dang Wei Anna Freydenzon Octave Guinebretiere Karim Zaidi Fen Yang Weimin Ye Niklas Hammar Karin Modig Naomi R. Wray Maria Feychting Nadine Hamieh Bruno Ventelou Beranger Lekens Laurene Gantzer Stanley Durrleman Allan McRae Baptiste Couvy-Duchesne Fang Fang Thomas Nedelec Stanley Durrleman Bruno Ventelou Thomas Nedelec Octave Guinebretiere Karim Zaidi Fang Fang Dang Wei Fen Yang Allan McRae Naomi Wray Baptiste Couvy-Duchesne Anna Freydenzon Lydie Tran Evans Cheruiyot |
| author_facet | Dang Wei Anna Freydenzon Octave Guinebretiere Karim Zaidi Fen Yang Weimin Ye Niklas Hammar Karin Modig Naomi R. Wray Maria Feychting Nadine Hamieh Bruno Ventelou Beranger Lekens Laurene Gantzer Stanley Durrleman Allan McRae Baptiste Couvy-Duchesne Fang Fang Thomas Nedelec Stanley Durrleman Bruno Ventelou Thomas Nedelec Octave Guinebretiere Karim Zaidi Fang Fang Dang Wei Fen Yang Allan McRae Naomi Wray Baptiste Couvy-Duchesne Anna Freydenzon Lydie Tran Evans Cheruiyot |
| author_sort | Dang Wei |
| collection | DOAJ |
| description | Summary: Background: Many studies have investigated early predictors for Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). However, evidence is sparse regarding specific and common predictors for these diseases. We aimed to identify medication use, health conditions, and blood biomarkers that might be associated with the risk of AD, PD, and ALS ten years later. Methods: We conducted population-based nested case–control studies of AD, PD, and ALS using electronic medical records in Europe (France, the UK, and Sweden) and Australia. We retrieved data on medication use, diagnosed health conditions, and measured blood biomarkers from electronic medical records or biomedical cohorts. Conditional logistic regression models and meta-analysis were applied to assess the associations between these factors and the risk of receiving a diagnosis of AD, PD, or ALS. Findings: We included a total of 149,642 AD cases (mean age: 79.1–81.2 years), 252,696 PD cases (73.2–75.9 years), and 27,533 ALS cases (64.4–69.6 years). The prescription of psychoanaleptics and nasal preparations was consistently associated with an increased risk of AD, PD, and ALS 5–10 years later. Constipation and use of related medications were associated with an increased risk of AD and PD, while diabetes and use of antidiabetics were associated with a reduced risk of ALS. A higher level of triglycerides was associated with a lower risk of AD, whereas a higher level of Apolipoprotein B was associated with a lower risk of PD, 5–10 years later. Interpretation: Psychoanaleptics and nasal preparations may serve as common predictors for diagnosis of AD, PD, and ALS 5–10 years later. Conversely, the increased prevalence of constipation is specific to AD and PD, while the decreased prevalence of diabetes and use of antidiabetics is specific to ALS. Funding: EU Joint Programme—Neurodegenerative Disease Research. |
| format | Article |
| id | doaj-art-ab3d5865ef6b422abd6054cc4cb3d5f3 |
| institution | Kabale University |
| issn | 2352-3964 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EBioMedicine |
| spelling | doaj-art-ab3d5865ef6b422abd6054cc4cb3d5f32025-02-06T05:12:01ZengElsevierEBioMedicine2352-39642025-03-01113105585Ten years preceding a diagnosis of neurodegenerative disease in Europe and Australia: medication use, health conditions, and biomarkers associated with Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosisResearch in contextDang Wei0Anna Freydenzon1Octave Guinebretiere2Karim Zaidi3Fen Yang4Weimin Ye5Niklas Hammar6Karin Modig7Naomi R. Wray8Maria Feychting9Nadine Hamieh10Bruno Ventelou11Beranger Lekens12Laurene Gantzer13Stanley Durrleman14Allan McRae15Baptiste Couvy-Duchesne16Fang Fang17Thomas Nedelec18Stanley DurrlemanBruno VentelouThomas NedelecOctave GuinebretiereKarim ZaidiFang FangDang WeiFen YangAllan McRaeNaomi WrayBaptiste Couvy-DuchesneAnna FreydenzonLydie TranEvans CheruiyotInstitute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Corresponding author. Institute of Environmental Medicine, Karolinska Institutet, Nobels väg 13, 17177, Stockholm, Sweden.Institute for Molecular Biosciences, The University of Queensland, Brisbane, AustraliaSorbonne University, Paris Brain Institute – ICM, CNRS, Inria, Inserm, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, FranceSorbonne University, Paris Brain Institute – ICM, CNRS, Inria, Inserm, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, FranceInstitute of Environmental Medicine, Karolinska Institutet, Stockholm, SwedenDepartment of Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, SwedenInstitute of Environmental Medicine, Karolinska Institutet, Stockholm, SwedenInstitute of Environmental Medicine, Karolinska Institutet, Stockholm, SwedenInstitute for Molecular Biosciences, The University of Queensland, Brisbane, Australia; Department of Psychiatry, University of Oxford, Oxford, UKInstitute of Environmental Medicine, Karolinska Institutet, Stockholm, SwedenSorbonne University, Paris Brain Institute – ICM, CNRS, Inria, Inserm, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, FranceAix-Marseille University, CNRS, IRD, AMSE, Marseille, FranceCegedim R&D, Boulogne-Billancourt, FranceCegedim R&D, Boulogne-Billancourt, FranceSorbonne University, Paris Brain Institute – ICM, CNRS, Inria, Inserm, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, FranceInstitute for Molecular Biosciences, The University of Queensland, Brisbane, AustraliaInstitute for Molecular Biosciences, The University of Queensland, Brisbane, Australia; Sorbonne University, Paris Brain Institute – ICM, CNRS, Inria, Inserm, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, FranceInstitute of Environmental Medicine, Karolinska Institutet, Stockholm, SwedenSorbonne University, Paris Brain Institute – ICM, CNRS, Inria, Inserm, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, FranceSummary: Background: Many studies have investigated early predictors for Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). However, evidence is sparse regarding specific and common predictors for these diseases. We aimed to identify medication use, health conditions, and blood biomarkers that might be associated with the risk of AD, PD, and ALS ten years later. Methods: We conducted population-based nested case–control studies of AD, PD, and ALS using electronic medical records in Europe (France, the UK, and Sweden) and Australia. We retrieved data on medication use, diagnosed health conditions, and measured blood biomarkers from electronic medical records or biomedical cohorts. Conditional logistic regression models and meta-analysis were applied to assess the associations between these factors and the risk of receiving a diagnosis of AD, PD, or ALS. Findings: We included a total of 149,642 AD cases (mean age: 79.1–81.2 years), 252,696 PD cases (73.2–75.9 years), and 27,533 ALS cases (64.4–69.6 years). The prescription of psychoanaleptics and nasal preparations was consistently associated with an increased risk of AD, PD, and ALS 5–10 years later. Constipation and use of related medications were associated with an increased risk of AD and PD, while diabetes and use of antidiabetics were associated with a reduced risk of ALS. A higher level of triglycerides was associated with a lower risk of AD, whereas a higher level of Apolipoprotein B was associated with a lower risk of PD, 5–10 years later. Interpretation: Psychoanaleptics and nasal preparations may serve as common predictors for diagnosis of AD, PD, and ALS 5–10 years later. Conversely, the increased prevalence of constipation is specific to AD and PD, while the decreased prevalence of diabetes and use of antidiabetics is specific to ALS. Funding: EU Joint Programme—Neurodegenerative Disease Research.http://www.sciencedirect.com/science/article/pii/S2352396425000295Neurodegenerative diseaseAlzheimer's diseaseParkinson's diseaseAmyotrophic lateral sclerosisMedicationsHealth conditions |
| spellingShingle | Dang Wei Anna Freydenzon Octave Guinebretiere Karim Zaidi Fen Yang Weimin Ye Niklas Hammar Karin Modig Naomi R. Wray Maria Feychting Nadine Hamieh Bruno Ventelou Beranger Lekens Laurene Gantzer Stanley Durrleman Allan McRae Baptiste Couvy-Duchesne Fang Fang Thomas Nedelec Stanley Durrleman Bruno Ventelou Thomas Nedelec Octave Guinebretiere Karim Zaidi Fang Fang Dang Wei Fen Yang Allan McRae Naomi Wray Baptiste Couvy-Duchesne Anna Freydenzon Lydie Tran Evans Cheruiyot Ten years preceding a diagnosis of neurodegenerative disease in Europe and Australia: medication use, health conditions, and biomarkers associated with Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosisResearch in context EBioMedicine Neurodegenerative disease Alzheimer's disease Parkinson's disease Amyotrophic lateral sclerosis Medications Health conditions |
| title | Ten years preceding a diagnosis of neurodegenerative disease in Europe and Australia: medication use, health conditions, and biomarkers associated with Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosisResearch in context |
| title_full | Ten years preceding a diagnosis of neurodegenerative disease in Europe and Australia: medication use, health conditions, and biomarkers associated with Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosisResearch in context |
| title_fullStr | Ten years preceding a diagnosis of neurodegenerative disease in Europe and Australia: medication use, health conditions, and biomarkers associated with Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosisResearch in context |
| title_full_unstemmed | Ten years preceding a diagnosis of neurodegenerative disease in Europe and Australia: medication use, health conditions, and biomarkers associated with Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosisResearch in context |
| title_short | Ten years preceding a diagnosis of neurodegenerative disease in Europe and Australia: medication use, health conditions, and biomarkers associated with Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosisResearch in context |
| title_sort | ten years preceding a diagnosis of neurodegenerative disease in europe and australia medication use health conditions and biomarkers associated with alzheimer s disease parkinson s disease and amyotrophic lateral sclerosisresearch in context |
| topic | Neurodegenerative disease Alzheimer's disease Parkinson's disease Amyotrophic lateral sclerosis Medications Health conditions |
| url | http://www.sciencedirect.com/science/article/pii/S2352396425000295 |
| work_keys_str_mv | AT dangwei tenyearsprecedingadiagnosisofneurodegenerativediseaseineuropeandaustraliamedicationusehealthconditionsandbiomarkersassociatedwithalzheimersdiseaseparkinsonsdiseaseandamyotrophiclateralsclerosisresearchincontext AT annafreydenzon tenyearsprecedingadiagnosisofneurodegenerativediseaseineuropeandaustraliamedicationusehealthconditionsandbiomarkersassociatedwithalzheimersdiseaseparkinsonsdiseaseandamyotrophiclateralsclerosisresearchincontext AT octaveguinebretiere tenyearsprecedingadiagnosisofneurodegenerativediseaseineuropeandaustraliamedicationusehealthconditionsandbiomarkersassociatedwithalzheimersdiseaseparkinsonsdiseaseandamyotrophiclateralsclerosisresearchincontext AT karimzaidi tenyearsprecedingadiagnosisofneurodegenerativediseaseineuropeandaustraliamedicationusehealthconditionsandbiomarkersassociatedwithalzheimersdiseaseparkinsonsdiseaseandamyotrophiclateralsclerosisresearchincontext AT fenyang tenyearsprecedingadiagnosisofneurodegenerativediseaseineuropeandaustraliamedicationusehealthconditionsandbiomarkersassociatedwithalzheimersdiseaseparkinsonsdiseaseandamyotrophiclateralsclerosisresearchincontext AT weiminye tenyearsprecedingadiagnosisofneurodegenerativediseaseineuropeandaustraliamedicationusehealthconditionsandbiomarkersassociatedwithalzheimersdiseaseparkinsonsdiseaseandamyotrophiclateralsclerosisresearchincontext AT niklashammar tenyearsprecedingadiagnosisofneurodegenerativediseaseineuropeandaustraliamedicationusehealthconditionsandbiomarkersassociatedwithalzheimersdiseaseparkinsonsdiseaseandamyotrophiclateralsclerosisresearchincontext AT karinmodig tenyearsprecedingadiagnosisofneurodegenerativediseaseineuropeandaustraliamedicationusehealthconditionsandbiomarkersassociatedwithalzheimersdiseaseparkinsonsdiseaseandamyotrophiclateralsclerosisresearchincontext AT naomirwray tenyearsprecedingadiagnosisofneurodegenerativediseaseineuropeandaustraliamedicationusehealthconditionsandbiomarkersassociatedwithalzheimersdiseaseparkinsonsdiseaseandamyotrophiclateralsclerosisresearchincontext AT mariafeychting tenyearsprecedingadiagnosisofneurodegenerativediseaseineuropeandaustraliamedicationusehealthconditionsandbiomarkersassociatedwithalzheimersdiseaseparkinsonsdiseaseandamyotrophiclateralsclerosisresearchincontext AT nadinehamieh tenyearsprecedingadiagnosisofneurodegenerativediseaseineuropeandaustraliamedicationusehealthconditionsandbiomarkersassociatedwithalzheimersdiseaseparkinsonsdiseaseandamyotrophiclateralsclerosisresearchincontext AT brunoventelou tenyearsprecedingadiagnosisofneurodegenerativediseaseineuropeandaustraliamedicationusehealthconditionsandbiomarkersassociatedwithalzheimersdiseaseparkinsonsdiseaseandamyotrophiclateralsclerosisresearchincontext AT berangerlekens tenyearsprecedingadiagnosisofneurodegenerativediseaseineuropeandaustraliamedicationusehealthconditionsandbiomarkersassociatedwithalzheimersdiseaseparkinsonsdiseaseandamyotrophiclateralsclerosisresearchincontext AT laurenegantzer tenyearsprecedingadiagnosisofneurodegenerativediseaseineuropeandaustraliamedicationusehealthconditionsandbiomarkersassociatedwithalzheimersdiseaseparkinsonsdiseaseandamyotrophiclateralsclerosisresearchincontext AT stanleydurrleman tenyearsprecedingadiagnosisofneurodegenerativediseaseineuropeandaustraliamedicationusehealthconditionsandbiomarkersassociatedwithalzheimersdiseaseparkinsonsdiseaseandamyotrophiclateralsclerosisresearchincontext AT allanmcrae tenyearsprecedingadiagnosisofneurodegenerativediseaseineuropeandaustraliamedicationusehealthconditionsandbiomarkersassociatedwithalzheimersdiseaseparkinsonsdiseaseandamyotrophiclateralsclerosisresearchincontext AT baptistecouvyduchesne tenyearsprecedingadiagnosisofneurodegenerativediseaseineuropeandaustraliamedicationusehealthconditionsandbiomarkersassociatedwithalzheimersdiseaseparkinsonsdiseaseandamyotrophiclateralsclerosisresearchincontext AT fangfang tenyearsprecedingadiagnosisofneurodegenerativediseaseineuropeandaustraliamedicationusehealthconditionsandbiomarkersassociatedwithalzheimersdiseaseparkinsonsdiseaseandamyotrophiclateralsclerosisresearchincontext AT thomasnedelec tenyearsprecedingadiagnosisofneurodegenerativediseaseineuropeandaustraliamedicationusehealthconditionsandbiomarkersassociatedwithalzheimersdiseaseparkinsonsdiseaseandamyotrophiclateralsclerosisresearchincontext AT stanleydurrleman tenyearsprecedingadiagnosisofneurodegenerativediseaseineuropeandaustraliamedicationusehealthconditionsandbiomarkersassociatedwithalzheimersdiseaseparkinsonsdiseaseandamyotrophiclateralsclerosisresearchincontext AT brunoventelou tenyearsprecedingadiagnosisofneurodegenerativediseaseineuropeandaustraliamedicationusehealthconditionsandbiomarkersassociatedwithalzheimersdiseaseparkinsonsdiseaseandamyotrophiclateralsclerosisresearchincontext AT thomasnedelec tenyearsprecedingadiagnosisofneurodegenerativediseaseineuropeandaustraliamedicationusehealthconditionsandbiomarkersassociatedwithalzheimersdiseaseparkinsonsdiseaseandamyotrophiclateralsclerosisresearchincontext AT octaveguinebretiere tenyearsprecedingadiagnosisofneurodegenerativediseaseineuropeandaustraliamedicationusehealthconditionsandbiomarkersassociatedwithalzheimersdiseaseparkinsonsdiseaseandamyotrophiclateralsclerosisresearchincontext AT karimzaidi tenyearsprecedingadiagnosisofneurodegenerativediseaseineuropeandaustraliamedicationusehealthconditionsandbiomarkersassociatedwithalzheimersdiseaseparkinsonsdiseaseandamyotrophiclateralsclerosisresearchincontext AT fangfang tenyearsprecedingadiagnosisofneurodegenerativediseaseineuropeandaustraliamedicationusehealthconditionsandbiomarkersassociatedwithalzheimersdiseaseparkinsonsdiseaseandamyotrophiclateralsclerosisresearchincontext AT dangwei tenyearsprecedingadiagnosisofneurodegenerativediseaseineuropeandaustraliamedicationusehealthconditionsandbiomarkersassociatedwithalzheimersdiseaseparkinsonsdiseaseandamyotrophiclateralsclerosisresearchincontext AT fenyang tenyearsprecedingadiagnosisofneurodegenerativediseaseineuropeandaustraliamedicationusehealthconditionsandbiomarkersassociatedwithalzheimersdiseaseparkinsonsdiseaseandamyotrophiclateralsclerosisresearchincontext AT allanmcrae tenyearsprecedingadiagnosisofneurodegenerativediseaseineuropeandaustraliamedicationusehealthconditionsandbiomarkersassociatedwithalzheimersdiseaseparkinsonsdiseaseandamyotrophiclateralsclerosisresearchincontext AT naomiwray tenyearsprecedingadiagnosisofneurodegenerativediseaseineuropeandaustraliamedicationusehealthconditionsandbiomarkersassociatedwithalzheimersdiseaseparkinsonsdiseaseandamyotrophiclateralsclerosisresearchincontext AT baptistecouvyduchesne tenyearsprecedingadiagnosisofneurodegenerativediseaseineuropeandaustraliamedicationusehealthconditionsandbiomarkersassociatedwithalzheimersdiseaseparkinsonsdiseaseandamyotrophiclateralsclerosisresearchincontext AT annafreydenzon tenyearsprecedingadiagnosisofneurodegenerativediseaseineuropeandaustraliamedicationusehealthconditionsandbiomarkersassociatedwithalzheimersdiseaseparkinsonsdiseaseandamyotrophiclateralsclerosisresearchincontext AT lydietran tenyearsprecedingadiagnosisofneurodegenerativediseaseineuropeandaustraliamedicationusehealthconditionsandbiomarkersassociatedwithalzheimersdiseaseparkinsonsdiseaseandamyotrophiclateralsclerosisresearchincontext AT evanscheruiyot tenyearsprecedingadiagnosisofneurodegenerativediseaseineuropeandaustraliamedicationusehealthconditionsandbiomarkersassociatedwithalzheimersdiseaseparkinsonsdiseaseandamyotrophiclateralsclerosisresearchincontext |